You are here

Article Text

Article menu
Download PDFPDF
Aetiology
Randomised controlled trial
Statins induce hyperglycaemia of uncertain importance
  1. Victor M Montori,
  2. Juan P Brito
  1. Division of Endocrinology, Diabetes, Metabolism and Nutrition, Mayo Clinic, Rochester, Minnesota, USA
  1. Correspondence to : Victor M Montori
    Division of Endocrinology, Diabetes, Metabolism and Nutrition Rochester, Mayo Clinic, Minnesota, USA; Montori.Victor{at}mayo.edu

http://dx.doi.org/10.1136/eb-2012-101030

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Commentary on: Ridker PM, Pradhan A, MacFadyen JG, et al. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012; 380:565–71.OpenUrlCrossRefPubMedWeb of Science

    Context

    Statins effectively reduce cardiovascular risk. Although generally safe, their use has been associated with muscle discomfort, myopathy, neuropathy and, rarely, rhadbomyolysis. Since February 2012, statin labels carry a new warning: their use is associated with elevated blood glucose levels.

    Whereas the mechanism remains unknown, several meta-analyses have substantiated the relationship between statin use and elevation of blood glucose levels. As glucose levels rise, some (those close to the threshold at the outset) will cross the arbitrary threshold for the diagnosis of diabetes. Meta-analyses …

    View Full Text

    Footnotes

    • Competing interests None.